Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patients

  • STATUS
    Not Recruiting
  • End date
    Nov 4, 2022
  • participants needed
    600
  • sponsor
    Amgen
Updated on 26 January 2021
Investigator
Amgen Call Center
Primary Contact
Hospital Quiron Madrid (3.7 mi away) Contact
+131 other location

Summary

The primary objective is to demonstrate the superiority of subcutaneous erenumab compared to oral prophylactic(s) on sustained benefit defined as % subjects completing one-year on the randomized treatment and achieving at least a 50% reduction from baseline in monthly migraine days at month 12.

Details
Condition Episodic Migraine
Treatment Erenumab, Oral Prophylactic
Clinical Study IdentifierNCT03927144
SponsorAmgen
Last Modified on26 January 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note